In order to improve the immunogenicity of HIV-1 envelope glycoproteins, we have fused gp120 to a carrier protein, hepatitis B surface antigen (HBsAg), which is capable of spontaneous assembly into virus-like particles. The HBsAg-gp120 hybrid proteins assembled efficiently into 20 -30 nm particles. The particles resemble native HBsAg particles in size and density, consistent with a lipid composition of about 25% and a gp120 content of about 100 per particle. Particulate gp120 folds in its native conformation and is biologically active, as shown by high affinity binding of CD4. The particles express conformational determinants targeted by a panel of broadly cross-reactive neutralizing antibodies, and they show tight packing of gp120. Because the particles are lipoprotein micelles, an array of gp120 on their surface closely mimics gp120 on the surface of HIV-1 virions. These gp120-rich particles can enhance the quality, as well as quantity, of antibodies elicited by a gp120 vaccine. Published by Elsevier Inc.
Introduction
HIV-1 infection induces a strong immune response in humans, including the production of cross-reactive neutralizing antibodies (Berkower et al., 1989; Steimer et al., 1991) . Envelope glycoprotein gp120 is the main target of these antibodies (Berkower et al., 1991) . Neutralizing human monoclonal antibodies have been described, which target conformational sites on gp120 (Buchacher et al., 1992; Burton et al., 1991; Thali et al., 1991) and a linear site on gp41 (Muster et al., 1993) . However, gp120-based HIV vaccines have been unable to elicit comparable titers and breadth of neutralizing antibodies Mascola et al., 1996) , and they have generally failed to demonstrate protection in human vaccine trials (Watanabe, 2003) . Limited potency of gp120 remains a major challenge for HIV-1 vaccine development (Poignard et al., 2001) .
For other viral antigens, vaccine potency has been enhanced by up to 1000-fold by assembly into virus-like particles. Successful vaccines such as hepatitis B surface antigen (HBsAg) (Cabral et al., 1978) , L1 protein of human papilloma virus (Kirnbauer et al., 1992) , and rabies vaccine (Piza et al., 2002) have depended on particle assembly for vaccine efficacy and protection. In these cases, enhanced vaccine potency could be manifested by increased antibody titer as well as improved antibody quality, with more antibodies targeting conformational neutralizing determinants on the virus.
For HIV antigens, assembly of immunogenic particles has been a long-term goal, and several carrier proteins have been tested for particle formation. These include hepatitis B core antigen (Grene et al., 1997; Patterson et al., 2001) , yeast retrotransposon Ty (Kingsman et al., 1995) , retrovirus gag protein (Lu et al., 1995; Tobin et al., 1996; Wagner et al., 1998) , bovine papilloma virus L1 protein (Liu et al., 2002) , and VSV virions (Rose et al., 2001) . In some cases, native gp120 was not expressed in the particles, and in others, the antigen density of gp120 per particle was limited.
In the present study, we have expressed gp120 as a fusion protein with hepatitis B surface antigen (HBsAg). By itself, HBsAg assembles 22 nm virus-like particles ( Schneider, 2001) , which are rich in protein and lipid. When expressed together with gp120, the HBsAg-gp120 hybrids assemble spontaneously and efficiently into virus-like particles. These particles express gp120 at a lipid -water interface and display the same conformational epitopes as found on virions. Enhanced vaccine potency of virus-like particles was demonstrated by the induction of neutralizing antibodies after fewer doses than with native gp120.
Results

Expression of HBsAg-gp120 hybrids by vaccinia recombinants
We previously identified a site at amino acid 42 of gp120 where foreign protein sequences could be linked to gp120 without disturbing its native folding and receptor binding (Patterson et al., 2001) . We have used this site to fuse gp120 with a carrier protein capable of self-assembly ( Fig. 1A ). Hepatitis B core antigen-gp120 hybrids folded correctly, but were unable to assemble as particles (Patterson et al., 2001 ). In the current study, we linked gp120 to HBsAg, using two closely related genes for HBsAg. One was amplified directly from hepatitis B virus to produce hybrid MR15. The other, in hybrid MR23, was a synthetic gene coding for the same amino acid sequence, but used codons optimized for mammalian gene expression (Haas et al., 1996) . Both HBsAg-gp120 hybrids were expressed in vaccinia recombinants and tested for gp120 antigenicity and particle assembly.
Expression of MR15 and MR23 was analyzed by immunoblot ( Fig. 2) . Cell lysates or purified particles were electrophoresed under reducing conditions and probed with monoclonal antibody M77, specific for the V3 loop of gp120 (left panel), or with goat polyclonal antibodies to HBsAg (right panel). The v55 control expressed native HBsAg and gave no gp120 band (lane 1). MR15 and MR23 hybrids, after deletion of the V1V2 domains and insertion of HBsAg, gave bands the same size (lanes 2 and 3) as native gp120 (lane 6). Because of glycosylation at six sites, the shorter V1V2 domain (80 amino acids) is predicted to have nearly the same mass as HBsAg (225 amino acids). MR23, with optimized codons for part of its sequence, expressed about twice as much protein as MR15. Purified MR23 particles contain this band (lane 5), indicating that HBsAg-gp120 is an intrinsic part of the particles. MR23 also showed a prominent band at about twice the expected size, indicating dimer formation. Dimers co-purified with MR23 particles, suggesting that the first step in particle assembly may be dimer formation, similar to native HBsAg (Huovila et al., 1992) . Western blots of MR15 and MR23 developed with anti-HBsAg showed that the hybrid band contains surface antigen, as well as gp120. All of the surface antigen banded at the size of the HBsAg-gp120 hybrid, indicating that hybrid particles contain gp120 and HBsAg in a one to one ratio.
Assembly of gp120-rich particles
Assembly of HBsAg-gp120 hybrids was assessed by sedimentation in a sucrose step gradient (Fig. 3 ). The hybrids sedimented at large size and banded at the 20-50% sucrose interface. In other experiments, the hybrid banded at a 20 -33% sucrose interface (data not shown). This is denser than native HBsAg, which forms a band at the 10-20% interface, and the band was broader than for native HBsAg, suggesting greater size heterogeneity. The particles were much larger than most other proteins, giving significant purification at this step. Efficient assembly is indicated by the fact that nearly all of the antigenic material sedimented at large size, and little or none remained at the top of the gradient.
Native HBsAg has been purified by banding in CsCl density gradients (Rizzetto et al., 1980) . Under similar conditions, the HBsAg-gp120 hybrid formed a broad band at a density of 1.21 -1.25 g/ml (Fig. 4 ). This was slightly denser than native HBsAg (1.20 -1.21 g/ml), but significantly lighter than most proteins. Low density of the MR15 particles is consistent with a composition similar to the 25% Each hybrid consisted of the hemagglutinin leader, followed by amino acids 2 -226 of HBsAg (or 1 -149 of core antigen) fused to amino acids 42 -503 of gp120, with deletion of the V1V2 loop (amino acids 125 -205). The viral gene for HBsAg was used in hybrid MR15, and a codon-optimized synthetic HBsAg gene was used in MR23. (B) Proposed structure for HBsAg-gp120 particles. Membrane-spanning HBsAg anchors gp120 to the particles, producing an array of gp120 molecules at a lipid -water interface. lipid found in native HBsAg particles (Ganem and Schneider, 2001) . The increased density relative to native HBsAg may reflect increased protein content due to the additional gp120 sequence attached to each molecule of HBsAg.
The CsCl banded material was analyzed by electron microscopy (Fig. 5 , left side). The MR15 hybrid formed spherical particles with a range of sizes between 15 and 30 nm in diameter. The particles resemble native HBsAg particles (right side). Native HBsAg particles contain 100 -200 copies of surface antigen per particle (Aggerbeck and Peterson, 1985) , with surface antigen spanning the lipid layer two to four times as an intrinsic membrane protein (Eble et al., 1987; Stirk et al., 1992) . On the basis of observed structural similarities, HBsAg-gp120 particles may have a comparable number of gp120 molecules arrayed on the particle surface and anchored to the micelle by surface antigen. This array of gp120 at the lipid -water surface of the particles duplicates gp120 on the surface of HIV-1 virions.
Assembly of mixed particles
Assembly of HBsAg particles occurs in a pre-Golgi compartment from available precursors (Huovila et al., 1992) . If two forms of HBsAg were expressed in the same cell, it should be possible to form mixed particles containing both precursors. We tested this hypothesis by co-expressing HBsAg-gp120 at the same time as native HBsAg, both at a multiplicity of infection of three per cell. As shown in Fig.  6 , the resulting mixed particles contained gp120, but their sedimentation profile was shifted dramatically. Instead of sedimenting in a broad band at the 20 -30% sucrose interface, they now band at the 10 -20% interface, the same as native HBsAg. This shift in sedimentation of gp120 suggests that HBsAg has been incorporated into the same particles as HBsAg-gp120 and has shifted their density and composition to be more like native HBsAg particles. As a Fig. 2 . Western blot of HBsAg-gp120 hybrids expressed by recombinant vaccinia virus. Twenty micrograms of protein from infected cell lysates, 3.6 Ag of sucrose gradient purified MR23 particles, or 120 ng of baculovirus-derived gp120 were reduced with 50 mM dithiothreitol, electrophoresed in a 3 -8% gel with Tris -acetate buffer, transferred to nitrocellulose, and probed with monoclonal antibody M77 to gp120. The v55 control expressed HBsAg alone. MR15 hybrid expressed in CV-1 cells (lane 2) was compared to MR23 expressed in CV-1 (lane 3) or HeLa cells (lane 4) or to purified MR23 (lane 5). In the right panel, the same MR15 and MR23 lysates were probed with polyclonal goat antibodies to HBsAg. Fig. 3 . Sucrose step gradient of MR15. MR15 cell lysate (2.4 ml) was layered onto a discontinuous sucrose gradient consisting of 50% sucrose (4.5 ml), 20% sucrose (2.5 ml), and 10% sucrose (2.5 ml), and sedimented 2.5 h at 39 000 rpm in a Beckman SW41 rotor. Fractions were assayed for gp120 content by ELISA. MR15 sedimented at large size, well separated from most proteins. Little or no antigen remained at the top of the gradient, indicating efficient assembly of particles. control, HBsAg-gp120 particles expressed separately and mixed with HBsAg particles before centrifugation did not shift their sedimentation profile (not shown).
Native conformation of gp120 in particles MR15 particles were characterized with a panel of human neutralizing monoclonal antibodies specific for conformational or discontinuous epitopes on gp120. Antibodies F105 and 1b12 are specific for the CD4 binding site and depend on the native conformation of gp120 (Thali et al., 1991) , while antibody 2G12 is specific for a discontinuous epitope that depends on glycosylation (Wyatt et al., 1998) . As shown in Fig. 7 , these antibodies all bound particulate gp120 with high affinity, similar to monomeric gp120, indicating that conformational sites recognized by these antibodies are present in the particles and in mono- HBsAg particles banded at a density of 1.20 -1.21 g/ml, consistent with a lipid content of 25%. MR15 banded at 1.21 -1.25 g/ml, although most other proteins were denser. . Co-expression of two antigens produces mixed particles. CV-1 cells were infected with MR23 (optimized HBsAg-gp120) without or with MR21 (optimized HBsAg alone) at a multiplicity of infection of three each. Cell lysates were sedimented through sucrose gradients, and fractions were assayed, using monoclonals specific for gp120 or HBsAg. By itself, MR23 banded at the 20 -30% sucrose interface. Co-infection with MR21 shifted the entire gp120 peak to the 10 -20% interface, where native HBsAg also bands. meric gp120. For comparison, conformation-independent mouse monoclonals M77 and D47 (see below) to the V3 loop bound equally well, although control monoclonal M107 (specific for the missing V1V2 region) did not bind. Particulate gp120 expressed all conformational neutralizing epitopes tested. This is important for a vaccine antigen, because a vaccine lacking these epitopes would be unable to elicit antibodies to these broadly shared neutralizing sites.
The conformation of gp120 in particles was probed with CD4-Ig, whose binding depends on the native conformation of the CD4 binding site (Kowalski et al., 1987) . CD4-Ig binding to MR15 particles was comparable to monomeric gp120, and both were half-maximal at about 2 nM (0.2 Ag/ ml in Fig. 8 ). Specificity for gp120 in the hybrid was shown by the failure to bind HBsAg alone. The CD4 binding site is an important target for broadly cross-reactive neutralizing antibodies (Berkower et al., 1991; Burton et al., 1991; Steimer et al., 1991; Thali et al., 1991) , so it is an essential feature of any particle vaccine. CD4-Ig binding to gp120 particles was blocked by pre-incubation with monoclonal antibody Q4120 (Healey et al., 1990) , which binds the Leu3a determinant (not shown). This result indicates that gp120 in particles binds the same site on CD4 as do gp120 monomers.
Antibodies specific for different assembled and maturational forms of gp120 were used to assess the status of gp120 in particles. Monoclonal M15 is specific for gp120 monomers and binds gp120 early after synthesis. But as gp120 matures, it assembles into trimers, and M15 binding is lost (Otteken et al., 1996) . Failure to bind M15 is a measure of gp120 assembly into trimers, as found in viral spikes (Weiss et al., 1990) . Monoclonal D47 binds all maturational forms of gp120, from monomer to trimer. As shown in Fig. 9 (right side), both monoclonals bound monomeric gp120. However, although D47 bound gp120 particles, M15 did not (left side). Lack of M15 binding suggests a qualitative difference between gp120 particles and free monomers.
In a control experiment, M15 bound a core antigen-gp120 hybrid as well as native gp120, but not the HBsAg- Fig. 7 . Characterization of gp120 particles with monoclonal antibodies to conformational sites. Microtiter plates were coated with 0.6 Ag/ml MR15 (left panel) or 1 Ag/ml gp120 (right panel), blocked with BSA, and incubated with monoclonal antibodies to the CD4 binding site (1b12 and F105) or to another conformation-dependent neutralizing site (2G12). For each monoclonal, binding to gp120 particles was determined when the binding to monomeric gp120 reached a plateau of 2 OD. Fig. 8 . CD4-Ig binding to gp120 particles. CD4-Ig was incubated in microtiter wells coated with gp120, MR15, or HBsAg, and binding was detected with enzyme-labeled goat anti-human IgG (Fc specific). CD4-Ig bound particulate gp120 with high affinity and specificity. gp120 particles (Fig. 10) . The core antigen-gp120 hybrid has the same V1V2 deletion as the HBsAg-gp120 hybrid, but it failed to assemble particles (Patterson et al., 2001) . Thus, failure of M15 binding was not due to the V1V2 deletion, but was due to particle formation. The lack of M15 binding suggests that gp120 particles are qualitatively different from and are not simply the sum of gp120 monomers. Packing interactions among neighboring gp120 mol- Fig. 9 . The assembled state of gp120 in particles was probed with monoclonal M15, which binds monomers but not assembled trimers of gp120, and monoclonal D47, which binds all forms of gp120. Wells were coated with MR15 (0.6 Ag/ml) or gp120 (0.8 Ag/ml). M15 bound gp120 monomers but not gp120 particles, suggesting that gp120 particles are qualitatively different from free gp120. Antibody concentration is expressed as 1/dilution of culture supernatant. Fig. 10 . Monoclonal M15 binding to core antigen-gp120 hybrid vs. HBsAg-gp120 hybrid. Both hybrids share the identical V1V2 deletion, but one is assembled (HBsAg hybrid) and the other is not (core antigen hybrid). M15 binds the unassembled gp120-core antigen hybrid, but not assembled gp120-HBsAg particles. Antibody concentration is expressed as dilution of M15 culture supernatant. ecules on the surface of particles may exclude M15 from binding, just as they do in mature HIV virions.
Neutralizing antibodies
The gene coding for HBsAg-gp120 hybrid MR23 was cloned into a baculovirus vector and expressed by infecting insect cells (Luckow et al., 1993) . The resulting gp120 particles were purified on a sucrose gradient and injected into rabbits in Freund's adjuvant. Rabbit neutralizing antibodies were measured in a single-step infectivity assay against HIV-1 pseudovirions expressing luciferase (Connor et al., 1995) . As shown in Fig. 11 , neutralizing antibodies appeared after two doses of the gp120 particle vaccine. Monomeric gp120, also expressed by baculovirus, required three doses to elicit comparable levels of neutralizing antibodies. Rabbit neutralizing activity against the homologous strain nearly equaled that of HIV immune globulin from infected people.
Discussion
For many viral antigens, particle formation is accompanied by a significant increase in vaccine potency. We have incorporated gp120 into virus-like particles to enhance its vaccine potency. In our construct, gp120 was fused to a carrier protein HBsAg that was capable of spontaneous assembly into particles. As the HBsAg part of the fusion protein assembled, it incorporated gp120 into the particles. Assembly was an efficient process, with very little gp120 antigen remaining as monomers. The surprising finding was that a small protein like HBsAg (25 kDa) could assemble particles, even when fused to a much larger protein like gp120 (95 kDa with a V1V2 deletion). Assembly may depend more on the flexibility of HBsAg and its molecular compatibility with gp120 than on relative size. The flexibility of HBsAg is suggested by its ability to assume different forms in nature, including 42 nm Dane particles (hepatitis B virus), 22 nm spherical particles, rods with a diameter of 22 nm (Ganem and Schneider, 2001) , and even 32 nm virions of hepatitis y virus (Rizzetto et al., 1980) . The topology of HBsAg in a lipid bilayer may be crucial to the formation of stable particles rich in gp120. According to the current model (Stirk et al., 1992) , HBsAg is an intrinsic membrane protein that spans the membrane four times, allowing it to anchor gp120 to the particles (Fig.  1B) . By expressing gp120 on a lipid surface, the particles recreate the natural milieu of gp120 on HIV virions. Native Fig. 11 . Neutralizing antibodies elicited by HBsAg-gp120 hybrids. Rabbits were immunized with 10 Ag of gp120 particles or monomeric gp120 expressed by baculovirus. After the second dose, neutralizing activity was measured against HIV pseudovirions bearing the homologous envelope glycoproteins. Neutralizing antibodies appeared earlier in rabbits immunized with gp120 particles.
HBsAg particles contain 100 copies of HBsAg per particle (Aggerbeck and Peterson, 1985) . Although HBsAg-gp120 particles are roughly the same size, their greater heterogeneity suggests that they may vary about an average content of 100 HBsAg-gp120 molecules per particle. The model also predicts that the amino and carboxyl ends of HBsAg, as well as a short hydrophilic sequence in the middle, are exposed on the surface of particles, which agrees with the limited protease sensitivity of HBsAg, except at these sites (Sonveaux et al., 1994) . The topology may explain the ability to link other antigens to the amino end (Bruss and Ganem, 1991; Stoute et al., 1997; Valenzuela et al., 1985) , the middle hydrophilic sequence (Delpeyroux et al., 1986; Eckhart et al., 1996) , or the carboxyl end (Bisht et al., 2002) of HBsAg, while still forming stable particles, as well as our success in attaching gp120 at the carboxyl end.
The maturation pathways for HBsAg and gp120 are similar, allowing particle assembly in the pre-Golgi compartments (Huovila et al., 1992) and folding and glycosylation in the Golgi. Compatibility in intracellular trafficking and membrane localization may also determine which proteins can be incorporated into HBsAg particles. Other enveloped viral glycoproteins smaller than gp120 have assembled into HBsAg particles, including glycoprotein D of herpes simplex virus type 1 (Valenzuela et al., 1985) and dengue virus envelope protein (Bisht et al., 2002) . This is the first report of native gp120 assembling into HBsAg particles.
Once incorporated into particles, gp120 demonstrated several properties that could contribute to vaccine potency. First, the CD4 binding domain is intact, as shown by binding CD4 with high affinity, as well as two human monoclonal antibodies specific for this site. This site is an important target for neutralizing antibodies made by infected humans (Berkower et al., 1991; Steimer et al., 1991) , and it is broadly shared among diverse HIV-1 isolates. Mutational escape at this site may be difficult, because it performs the essential viral function of receptor binding. In addition, neutralization targeting this site may proceed by an efficient mechanism that causes viral inactivation when as few as 2% of sites are bound by CD4-Ig (Berkower et al., 1996) .
Second, gp120 particles bound well to every neutralizing monoclonal tested, including antibodies specific for conformational sites such as F105, 1b12, and 2G12. Particulate gp120 has multiple neutralizing epitopes, each in the native conformation. This should help broaden the antibody response to non-vaccine strains, because crossreactive neutralizing antibodies are often specific for conformational sites on gp120 (Berkower et al., 1989 (Berkower et al., , 1991 . It may also increase the neutralizing titer, because a combination of antibodies to different epitopes can produce additive or even synergistic neutralizing effects on HIV-1 (Li et al., 1997) . A combination of neutralizing monoclonal antibodies to these determinants (plus monoclonal 2F5 against gp41) completely protected rhesus macaques against SHIV challenge (Baba et al., 2000; Mascola et al., 2000) . By eliciting active immunity to these determinants, a gp120 particle vaccine could achieve one important goal of vaccination, which is to elicit broadly crossreactive neutralizing antibodies.
Third, as shown in the model (Fig. 1B) , the overall design of gp120 particles resembles the surface of HIV virus, with about 100 copies of gp120 arrayed on the surface of each particle at a lipid -water interface. Oligomeric forms of gp120 have shown activity as vaccine antigens. Native gp140 trimers, corresponding to the HIV-1 viral spike, have elicited novel antibodies (Earl et al., 1994) and have protected rhesus macaques against SHIV challenge (Earl et al., 2001) . Aldrithiol-2-inactivated HIV-1 virions, with 21 -42 gp120 molecules per particle (Arthur et al., 1998; Chertova et al., 2002) , have boosted neutralizing antibodies and have helped to control viremia after a pathogenic SHIV challenge (Willey et al., 2003) . The greater antigen density of HBsAg-gp120 particles, due to more antigen on a smaller particle, may contribute even more to vaccine potency.
Each of these factors may contribute to the enhanced potency of gp120 particles, as shown by their ability to elicit neutralizing antibodies after fewer doses of vaccine. Particles may enhance vaccine potency by improving the quantity and quality of antibodies elicited. Immunization with particles is believed to deliver a strong stimulus to B cells through cross-linking of surface immunoglobulin, which also makes them more responsive to T cell help (Bachmann and Zinkernagel, 1997) . In addition, because enveloped particles so closely resemble enveloped virus, a greater proportion of antibodies may bind conformational sites on the virus, including neutralizing determinants. Enveloped particles may be a good substitute for inactivated viral vaccines, because they avoid the risk of infection due to incomplete inactivation.
Our finding that co-expression of two vaccinia recombinants can produce mixed HBsAg particles is consistent with earlier observations that co-expression of small-and middlesized HBsAg produced mixed particles (Cheng and Moss, 1987) , as did co-expression of surface antigens from human and woodchuck hepatitis viruses (Gerhardt and Bruss, 1995) . This would allow expression of two different viral proteins or two different gp120 variants in the same particle. It also raises the interesting possibility of combining antigens and cytokines in the same particle to enhance or modulate the immune response to the antigen. For example, DNA vaccines linking HBsAg with IL-2 have been reported to enhance the immune response to HBsAg (Chow et al., 1997) .
Our results indicate that envelope glycoproteins nearly as large as gp120 can be efficiently incorporated into HBsAgcontaining virus-like particles, while retaining their native conformation. By creating an array of gp120 molecules in their natural milieu on a lipid surface, these particles can improve the quality and quantity of antibodies elicited by immunization.
Materials and methods
Cells
CV-1, HeLa, and tk-cells were obtained from Dr. Michael Merchlinsky (CBER, Bethesda, MD) and were grown in Dulbecco's modified medium supplemented with 10% FCS, penicillin and streptomycin, and glutamine.
Proteins and antibodies
HBsAg was a gift from Dr. James Shih (NIH blood bank), gp120 expressed in baculovirus was from Protein Sciences (Meriden, CT) (Cochran et al., 1987) , and CD4-Ig was a gift from Dr. Phil Berman (Genentech, South San Francisco, CA) (Capon et al., 1989) .
Mouse monoclonal antibodies to the V3 loop of gp120 included M77 (Pal et al., 1992) from Advanced Biotechnologies (Columbia, MD) and D47 (Otteken et al., 1996) from Dr. Pat Earl (NIAID, NIH) . Mouse monoclonal M15 (Otteken et al., 1996) was specific for gp120 monomers and would not bind assembled forms. Human neutralizing monoclonal antibodies to gp120 were obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, and included F105 from Dr. Marshall Posner (Posner et al., 1993; Thali et al., 1991) , IgG1 b12 from Dr. Dennis Burton and Carlos Barbas (Burton et al., 1991) , both specific for the CD4 binding site, and 2G12 from Dr. Hermann Katinger (Buchacher et al., 1992) , specific for a carbohydratedependent site. Affinity-purified goat anti-human IgG antibodies and goat anti-mouse IgG antibodies coupled to alkaline phosphatase were obtained from Cappel Labs (West Chester, PA).
Generation of recombinant vaccinia virus
DNA coding for Hepatitis B surface antigen was PCR amplified from pECO63 (ATCC, Manassas, VA) using primers CCGAATTCATCACAT CAGGATTCCTAGG (RB5) and CAGGTACCCAATGTATACCCAGAGACA (RB6). The 690 bp product was cut with EcoRI and KpnI and ligated into plasmid MR9 described previously (Patterson et al., 2001) , in place of the gene for core antigen. The resulting plasmid, MR15 (Fig. 1) , codes for the influenza hemagglutinin leader, followed by residues 2 -226 of hepatitis B surface antigen in tandem with HIV IIIB envelope glycoprotein gp120 residues 42 -125 and 205 -503, corresponding to deletion of the V1V2 loops. This deletion has no effect on CD4 binding (Pollard et al., 1992) . At the HBsAg-gp120 junction, the last four amino acids of HBsAg, WVYI, replace a homologous sequence in gp120 VTWIYY.
Recombinant vaccinia virus was generated from plasmid MR15 by transformation and co-infection of CV-1 cells with wild-type vaccinia virus (Earl and Moss, 1991) . Vaccinia recombinants were grown on tk-monolayers under BudR selection. Beta-galactosidase positive plaques were expanded twice on tk-cells grown in 12-well plates. Cell lysates were screened for gp120 expression by antigen capture ELISA on microtiter plates coated with mouse monoclonal M77. Bound gp120 hybrid was detected with HIV-Ig (pooled human antibodies to HIV-1), followed by enzymelabeled goat anti-human IgG. Vaccinia recombinants expressing gp120 hybrids were plaque purified at least three times and expanded on CV-1 cells.
Construction of a synthetic gene for HBsAg using optimized codons
A fully synthetic HBsAg gene was generated, in which optimized codons were substituted for viral codons (Haas et al., 1996) . It was made by PCR amplification of a series of 40-base pair primers with 20 base overlaps (Stemmer et al., 1995) . The resulting full-length gene was cloned, and four clones were sequenced. One had a single base error that was repaired by PCR, resulting in a complete HBsAg gene optimized for protein expression (Fig. 12 ). Synthesis and sequence analysis were performed by ATG Laboratories (Eden Prairie, MN) . The synthetic gene was cut with EcoRI and KpnI and inserted in place of natural HBsAg in plasmid MR15 to create MR23. MR23 was used to generate vaccinia recombinants as described above. Fig. 12 . Nucleotide and amino acid sequences of the synthetic HBsAg gene based on optimized codons. Five amino acids were added at the carboxyl end, and one was substituted near the amino end (underlined). This gene was expressed in tandem with gp120 in the MR23 hybrid.
Sucrose gradient centrifugation
Discontinuous sucrose gradients consisted of layers of 50 or 33%, 20%, and 10% sucrose in ultracentrifuge tubes. Lysates were prepared from about 200 Â 10 6 cells by freezing and thawing cells three times, followed by sonication for 30 s and centrifugation for 10 min at 12 000 rpm in a Sorvall SS-34 rotor. The clarified supernatant (2.5 ml) was layered onto sucrose and sedimented 2.5 h at 39 000 rpm in a Beckman SW41 rotor. Fractions were collected from the bottom and assayed for antigen by ELISA and for protein by BCA reagent (Pierce Chemical, Rockford, IL). Peak fractions were pooled, diluted in PBS, and centrifuged overnight at 32 000 rpm in a Beckman 35 rotor to concentrate the particles. Pellets were resuspended in PBS and stored frozen.
CsCl gradients
Culture supernatant from 1.8 Â 10 8 cells expressing MR15 was clarified by centrifugation for 10 min at 12 000 rpm in a Sorvall GSA rotor, followed by pelleting in a Beckman 45 Ti rotor for 2 h at 40 000 rpm. The pellet was resuspended in PBS, added to CsCl at a final concentration of 1.70 M, and centrifuged 18 h at 62 000 rpm in a Beckman NVT 90 rotor. Fractions were collected and assayed for gp120 content by ELISA.
ELISA assay of gp120
Sucrose gradient fractions were diluted 1:8 in PBS and added to wells of flexible microtiter plates (Falcon 3912). These were incubated overnight at 4 jC, then blocked with 1% BSA. Detection of gp120 was with monoclonal antibody 2G12, at 1 Ag/ml for 2 h at room temperature. Plates were washed in PBS + 0.1% Tween + 0.1% BSA + 0.02% sodium azide, and bound antibody was detected with alkaline phosphatase labeled, affinity purified, goat anti-human IgG. After 1 3/4 h, the plates were washed and phosphatase substrate (Sigma 104) was added. Antigen content, read as OD410 in a Dynatech MR5000 plate reader, was compared to a gp120 standard curve to determine antigen content in micrograms.
To measure the binding of monoclonal antibodies or CD4-Ig to HBsAg-gp120 particles, ELISA plates were coated overnight at 4 jC with sucrose-purified hybrid at 0.6 Ag/ml, or baculo-derived gp120 at 1 Ag/ml, followed by blocking with bovine serum albumin at 10 mg/ml. Serial dilutions of each monoclonal antibody were added to each well and incubated as described above, followed by detection with affinity-purified goat anti-human IgG coupled to alkaline phosphatase.
